Understand the source comparison
The muscle mass versus function disconnect
Perhaps the most surprising finding across the myostatin inhibitor field is that more muscle does not always mean better function. Both ACE-031 and ACE-083 produced measurable increases in muscle mass (by DXA and MRI), but neither consistently translated those
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Perhaps the most surprising finding across the myostatin inhibitor field is that more muscle does not always mean better function. Both ACE-031 and ACE-083 produced measurable increases in muscle mass (by DXA and MRI), but neither consistently translated those gains into improved functional outcomes like walking distance or muscle strength.
- This challenges a fundamental assumption in the muscle-building space: that bigger equals better. The quality of new muscle tissue, its fiber type composition, innervation, vascular supply, and contractile properties, may matter as much as its volume. Researchers evaluating muscle growth peptides should consider functional endpoints alongside mass measurements.